Intensifying insulin therapy in type 2 diabetes mellitus: Dosing options for insulin analogue premixes

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1630-1642

  Tibaldi, Joseph M ^a  

^a FLUSHING HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Aspart; Biphasic insulin analog; Detemir; Glargine; Lispro; Neutral protamine Hagedorn

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

DRUG DOSE INCREASE; DRUG EFFICACY; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INSULIN;

EID: 82855166069     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.019     Document Type: Review

References (61)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32(Suppl 1):S62-S67. American Diabetes Association.
2. National Diabetes Fact Sheet: United States, 2005 2005, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, Ga.
3. National Diabetes Fact Sheet, 2007 2007, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, Ga.
4. Number (in millions) of civilian, non-institutionalized persons with diagnosed diabetes, United States, 1980-2008 Centers for Disease Control and Prevention, Accessed March 14, 2011. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
5. Narayan K.M., Boyle J.P., Geiss L.S., et al. Impact of recent increase in incidence on future diabetes burden: United States, 2005-2050. Diabetes Care 2006, 29:2114-2116.
6. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
7. Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61. American Diabetes Association.
8. Cefalu W.T. Glycemic targets and cardiovascular disease. N Engl J Med 2008, 358:2633-2635.
9. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
10. Polonsky K.S., Given B.D., van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988, 81:442-448.
11. Vazquez-Carrera M., Silvestre J.S. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004, 26:445-461.
12. Gough S.C., Tibaldi J. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review. Clin Drug Invest 2007, 27:299-324.
13. Baron A.D., Kim D., Weyer C. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2:63-82.
14. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
15. 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23:813-819.
16. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000, 23:644-649.
17. Luzio S.D., Beck P., Owens D.R. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with type 2 diabetes. Horm Metab Res 2003, 35:434-438.
18. Garber A.J., Clauson P., Pedersen C.B., Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc 2007, 55:1735-1740.
19. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28:1107-1112.
20. Monnier L., Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006, 32:7-13.
21. Kumar A., Kalra S. Insulin initiation and intensification: insights from new studies. J Assoc Physicians India 2011, 59(Suppl):17-22.
22. Clinical guideline for pharmacological management of type 2 diabetes, 1/09/2009 (updated 11/2010) Joslin Diabetes Center and Joslin Clinic, Accessed March 10, 2011. http://www.joslin.org/bin_from_cms/Pharma_guideline_11._10.pdf.
23. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.
24. Meneghini L., Koenen C., Weng W., Selam J.L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab 2007, 9:902-913.
25. Fajardo Montanana C., Hernandez Herrero C., Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients-the PREDICTIVE BMI clinical trial. Diabet Med 2008, 25:916-923.
26. Philis-Tsimikas A., Charpentier G., Clauson P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006, 28:1569-1581.
27. NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, rDNA origin) [prescribing information] 2010, Novo Nordisk Inc, Princeton, NJ.
28. Humalog Mix 75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection, rDNA origin) [prescribing information] 2009, Eli Lilly, Indianapolis, Ind.
29. Humalog Mix 50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection, rDNA origin) [prescribing information] 2009, Eli Lilly, Indianapolis, Ind.
30. Humulin 70/30 (70% human insulin isophane suspension and 30% human insulin injection, rDNA origin) [prescribing information] 2011, Eli Lilly, Indianapolis, Ind.
31. Novolin 70/30 (70% NPH, human insulin isophane suspension and 30% regular, human insulin injection, rDNA origin) [prescribing information] 2010, Novo Nordisk Inc, Princeton, NJ.
32. Garber A.J. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006, 66:31-49.
33. Hermansen K., Colombo M., Storgaard H., et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002, 25:883-888.
34. Malone J.K., Yang H., Woodworth J.R., et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000, 26:481-487.
35. Mattoo V., Milicevic Z., Malone J.K., et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003, 59:137-143.
36. Boehm B.O., Home P.D., Behrend C., et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002, 19:393-399.
37. Coscelli C., Iacobellis G., Calderini C., et al. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol 2003, 40:187-192.
38. Roach P., Yue L., Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999, 22:1258-1261.
39. Heise T., Heinemann L., Hovelmann U., et al. Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care 2009, 32:1431-1433.
40. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006, 8:58-66.
41. Khutsoane D., Sharma S.K., Almustafa M., et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab 2008, 10:212-222.
42. Jang H.C., Guler S., Shestakova M. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help?. Results from a subanalysis of the PRESENT study. Int J Clin Pract 2008, 62:1013-1018.
43. Valensi P., Benroubi M., Borzi V., et al. The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008, 62:1809-1819.
44. Gumprecht J., Benroubi M., Borzi V., et al. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009, 63:966-972.
45. Raskin P.R., Hollander P.A., Lewin A., et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007, 18:56-62.
46. Liebl A., Prager R., Binz K., et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009, 11:45-52.
47. Buse J.B., Wolffenbuttel B.H., Herman W.H., et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009, 32:1007-1013.
48. Miser W.F., Arakaki R., Jiang H., et al. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010, 32:896-908.
49. Roach P., Trautmann M., Arora V., et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin-protamine formulations, insulin lispro Mix25. Clin Ther 1999, 21:523-534.
50. Malone J.K., Kerr L.F., Campaigne B.N., et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004, 26:2034-2044.
51. Rosenstock J., Ahmann A.J., Colon G., et al. Advancing insulin therapy in type 2 diabetes, previously treated with Glargine plus oral agents: prandial premixed (Lispro/ILPS) vs. basal/bolus (Glargine/Lispro) therapy. Diabetes Care 2008, 31:20-25.
52. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention US Food and Drug Administration, Center for Drug Evaluation and Research, Accessed June 14, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf.
53. Jain S.M., Mao X., Escalante-Pulido M., et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010, 12:967-975.
54. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(Suppl 1):4-68. American Association of Clinical Endocrinologists.
55. Ligthelm R.J. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Primary Care Diabetes 2009, 3:97-102.
56. Unnikrishnan A.G., Tibaldi J., Hadley-Brown M., et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009, 63:1571-1577.
57. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
58. Moses A.C., Raskin P., Khutoryansky N. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions?. Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabet Med 2008, 25:200-205.
59. Fahrbach J., Jacober S., Jiang H., Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol 2008, 2:831-838.
60. Hirsch I.B., Bergenstal R.M., Parkin C.G., et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005, 23:78-86.
61. Buse J.B., Wolffenbuttel B.H., Herman W.H., et al. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care 2011, 34:249-255.